Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)
SCNI moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How SCNI actually reacts to news — the realized, point-in-time move the market made, measured across 160 labeled events over the last three years with zero look-ahead.
SCNI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 52% | 119 |
| 30-min | 0.00% | 47% | 144 |
| 60-min | 0.00% | 47% | 150 |
| to close | 0.00% | 49% | 158 |
| Middle 50% of SCNI reactions | -1.47% to +2.36% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 160 |
Half of all Scinai Immunotherapeutics Ltd. - American Depositary Shares news events land between -1.47% and +2.36% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SCNI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SCNI's baseline. Nothing else.
Recent SCNI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing | Press release | PR Newswire | — | — | |
| Form 6-K Scinai Immunotherapeutic For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | +0.01% | -12.51% | |
| Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement | Press release | PR Newswire | +7.98% | -9.68% | |
| Form 6-K Scinai Immunotherapeutic For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.07% | +4.90% | |
| Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement | Press release | PR Newswire | +6.75% | +12.53% | |
| Form 6-K Scinai Immunotherapeutic For: Oct 13 | SEC filing · Form 6-K | SEC EDGAR | +1.27% | -21.66% | |
| Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement | Press release | PR Newswire | +1.27% | -21.66% | |
| Form EFFECT Scinai Immunotherapeutic | SEC filing · Form EFFECT | SEC EDGAR | +0.16% | -3.17% | |
| Form F-1 Scinai Immunotherapeutic | SEC filing · Form F-1 | SEC EDGAR | +0.00% | -9.88% | |
| Form 6-K Scinai Immunotherapeutic For: Sep 21 | SEC filing · Form 6-K | SEC EDGAR | +5.56% | -1.17% | |
| Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | PR Newswire | +5.56% | -1.17% | |
| Form 6-K Scinai Immunotherapeutic For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -2.78% | -5.56% | |
| Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business | Press release | PR Newswire | -5.66% | -2.86% | |
| Form EFFECT Scinai Immunotherapeutic | SEC filing · Form EFFECT | SEC EDGAR | +7.35% | +2.04% | |
| Form POS AM Scinai Immunotherapeutic | SEC filing · Form POS | SEC EDGAR | -2.47% | -3.60% | |
| Form 6-K Scinai Immunotherapeutic For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.35% | +0.70% | |
| Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum | Press release | PR Newswire | -2.46% | -3.69% | |
| Form 6-K Scinai Immunotherapeutic For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | +2.00% | +16.45% | |
| Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration | Press release | PR Newswire | — | — | |
| Form 6-K Scinai Immunotherapeutic For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | -2.29% | -3.71% | |
| Form 6-K Scinai Immunotherapeutic For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | -0.73% | +7.18% | |
| Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives | Press release | PR Newswire | +1.31% | +6.86% | |
| Form 6-K Scinai Immunotherapeutic For: Jun 08 | SEC filing · Form 6-K | SEC EDGAR | +2.16% | +1.14% | |
| Form EFFECT Scinai Immunotherapeutic | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -5.67% | |
| Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility | Press release | PR Newswire | +0.00% | -5.67% | |
| Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe | Press release | PR Newswire | +3.96% | +5.14% | |
| Form 6-K Scinai Immunotherapeutic For: May 12 | SEC filing · Form 6-K | SEC EDGAR | +0.06% | -4.62% | |
| Form 6-K Scinai Immunotherapeutic For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.93% | +5.15% | |
| Form F-3 Scinai Immunotherapeutic | SEC filing · Form F-3 | SEC EDGAR | +5.35% | -9.20% | |
| Form 6-K Scinai Immunotherapeutic For: Apr 27 | SEC filing · Form 6-K | SEC EDGAR | -0.16% | +7.97% | |
| Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing | Press release | PR Newswire | +30.72% | -1.73% | |
| Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities | Press release | PR Newswire | -0.30% | +1.43% | |
| Form 20-F Scinai Immunotherapeutic For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -1.68% | +4.94% | |
| Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration | Press release | PR Newswire | -1.68% | +4.94% | |
| Form 6-K Scinai Immunotherapeutic For: Mar 23 | SEC filing · Form 6-K | SEC EDGAR | — | -2.84% | |
| Form 6-K Scinai Immunotherapeutic For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | — | +0.67% | |
| Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 | Press release | PR Newswire | +0.00% | +2.17% | |
| Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price | Press release | PR Newswire | — | -3.95% | |
| Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept | Press release | PR Newswire | -5.52% | -4.48% | |
| Form 6-K Scinai Immunotherapeutic For: Feb 25 | SEC filing · Form 6-K | SEC EDGAR | +1.34% | +5.80% | |
| Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform | Press release | PR Newswire | +2.38% | +8.33% | |
| Form 6-K Scinai Immunotherapeutic For: Feb 17 | SEC filing · Form 6-K | SEC EDGAR | +3.17% | +0.00% | |
| Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm | Press release | PR Newswire | +3.17% | +0.00% | |
| Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL | Press release | PR Newswire | — | -1.24% | |
| Form 6-K Scinai Immunotherapeutic For: Dec 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.46% | |
| Form 6-K Scinai Immunotherapeutic For: Dec 02 | SEC filing · Form 6-K | SEC EDGAR | — | +1.98% | |
| Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances | Press release | PR Newswire | +3.96% | +1.98% | |
| Form S-8 Scinai Immunotherapeutic | SEC filing · Form S-8 | SEC EDGAR | — | -0.46% | |
| Form 6-K Scinai Immunotherapeutic For: Oct 06 | SEC filing · Form 6-K | SEC EDGAR | +0.71% | -3.21% | |
| Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities | Press release | PR Newswire | +0.71% | -3.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SCNI section they belong to.
Where else SCNI is measured.
SCNI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Scinai Immunotherapeutics Ltd. - American Depositary Shares's median reaction calculated?
Every labeled SCNI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 160 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of SCNI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SCNI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.